Sign in Subscribe
Scientists

p12CDK2-AP1 Associated with Tumor Progression and Poor Prognosis in Esophageal Squamous Cell Carcinoma

Strategic Insights

— 1 min read

Researchers in Honjo, Japan have discovered a significant association between p12CDK2-AP1 expression and tumor progression in esophageal squamous cell carcinoma (ESCC). The study, published in Oncology Reports, found that a reduction in p12CDK2-AP1 expression is linked to increased tumor aggressiveness and poor prognosis in patients with ESCC. The team conducted immunohistochemical examinations on 120 resected ESCC specimens, determining that 65.8% showed positive staining for p12CDK2-AP1, while 34.2% lacked the staining.

Key Takeaways:

  • p12CDK2-AP1 is a growth suppressor that negatively regulates cyclin-dependent kinase 2 (CDK2) activities, interfering with DNA replication.
  • A reduction in p12CDK2-AP1 expression is a negative prognostic indicator in patients with oral squamous cell carcinoma.
  • The study found that 79 out of 120 ESCC specimens showed positive staining for p12CDK2-AP1, while 41 lacked the staining.
  • p12CDK2-AP1 down-regulation is associated with tumor aggressiveness and poor prognosis in patients with ESCC.
  • The results suggest that p12CDK2-AP1 may be a useful biomarker for predicting ESCC progression and patient outcomes.
  • The study highlights the importance of further research into the role of p12CDK2-AP1 in ESCC and its potential as a therapeutic target.

Statistics:

  • 65.8% of ESCC specimens showed positive staining for p12CDK2-AP1.
  • 34.2% of ESCC specimens lacked p12CDK2-AP1 staining.
  • 79 out of 120 ESCC specimens showed p12CDK2-AP1 expression.
  • 41 out of 120 ESCC specimens lacked p12CDK2-AP1 expression.

Sources:

  • Hiyoshi Y. et al. (2009). p12 CDK2-associating protein 1 (p12CDK2-AP1) is associated with tumor progression and a poor prognosis in esophageal squamous cell carcinoma. Oncology Reports, 22(1), 35-39.
  • Kumamoto University Hospital. Dept. of Gastroenterological Surgery, Graduate School of Medical Sciences, Honjo, Kumamoto, Japan.
  • S. Karger AG, Allschwilerstrasse 10, CH-4009 Basel, Switzerland.

Read more